Turbiditas carbonatadas del Cretácico inferior en el Arroyo Bercho, Prebético de Jaén: Interpretación genética e implicaciones paleogeográficas

[ES] El análisis de las características sedimentarias de las turbiditas carbonatadas permite precisar la interpretación paleogeográfica del Prebético de Jaén, durante el Cretácico. Se pueden distinguir dos asociaciones de facies: a) Turbiditas de estatificación fina, intercaladas en abundante sedimento pelágico, e interpretadas como facies de borde de lóbulo. b) Cuerpos turbidíticos lenticulares interpretados como lóbulos de depósito formados por agradación. Aparecen asociadas a una serie depositada en una cuenca que progresivamente se fue haciendo más somera y que terminó con la implantación de una plataforma carbonatada en el Cenomanense. Se calcula que el depósito de las turbidítas debió realizarse a unos pocos centenares de metros de profundidad.[EN] The analysis of the sedimentary characteristics of the carbonate turbidites allows to accurate the paleogeographic interpretation of the Prebetie of laen. Two types of facies associations can be distinguished: a) Thin bedded turbidites> as intercalations into mainly hemipelapic sediments, interpreted as lobe fringe facies, b) Lents like turbiditie bodies corresponding to agradational depositional lobes. They occur associated to an shallowing upward sequence ending with Cenomanian carbonated platform facies. The turbiditic deposit supodselly took place in a few hundreds meters deep sedimentary basin.Trabajo patrocinado por la C.A.I.C.Y.T., dentro del proyecto «El Mesozoico de las Cordilleras Béticas» realizado en este centro del C.S.I.C.Peer reviewe

Bulk dynamics for interfacial growth models

We study the influence of the bulk dynamics of a growing cluster of particles on the properties of its interface. First, we define a {\it general bulk growth model} by means of a continuum Master equation for the evolution of the bulk density field. This general model just considers arbitrary addition of particles (though it can be easily generalized to consider substraction) with no other physical restriction. The corresponding Langevin equation for this bulk density field is derived where the influence of the bulk dynamics is explicitly shown. Finally, when it is assumed a well-defined interface for the growing cluster, the Langevin equation for the height field of this interface for some particular bulk dynamics is written. In particular, we obtain the celebrated Kardar-Parisi-Zhang (KPZ) equation. A Monte Carlo simulation illustrates the theoretical results.Comment: 6 pages, 2 figure

First-order phase transition in a 2D random-field Ising model with conflicting dynamics

The effects of locally random magnetic fields are considered in a nonequilibrium Ising model defined on a square lattice with nearest-neighbors interactions. In order to generate the random magnetic fields, we have considered random variables $\{h\}$ that change randomly with time according to a double-gaussian probability distribution, which consists of two single gaussian distributions, centered at $+h_{o}$ and $-h_{o}$, with the same width $\sigma$. This distribution is very general, and can recover in appropriate limits the bimodal distribution ($\sigma\to 0$) and the single gaussian one ($ho=0$). We performed Monte Carlo simulations in lattices with linear sizes in the range $L=32 - 512$. The system exhibits ferromagnetic and paramagnetic steady states. Our results suggest the occurence of first-order phase transitions between the above-mentioned phases at low temperatures and large random-field intensities $h_{o}$, for some small values of the width $\sigma$. By means of finite size scaling, we estimate the critical exponents in the low-field region, where we have continuous phase transitions. In addition, we show a sketch of the phase diagram of the model for some values of $\sigma$.Comment: 13 pages, 9 figures, accepted for publication in JSTA

Asteroseismology with the WIRE satellite. I. Combining Ground- and Space-based Photometry of the Delta Scuti Star Epsilon Cephei

We have analysed ground-based multi-colour Stromgren photometry and single-filter photometry from the star tracker on the WIRE satellite of the delta scuti star Epsilon Cephei. The ground-based data set consists of 16 nights of data collected over 164 days, while the satellite data are nearly continuous coverage of the star during 14 days. The spectral window and noise level of the satellite data are superior to the ground-based data and this data set is used to locate the frequencies. However, we can use the ground-based data to improve the accuracy of the frequencies due to the much longer time baseline. We detect 26 oscillation frequencies in the WIRE data set, but only some of these can be seen clearly in the ground-based data. We have used the multi-colour ground-based photometry to determine amplitude and phase differences in the Stromgren b-y colour and the y filter in an attempt to identify the radial degree of the oscillation frequencies. We conclude that the accuracies of the amplitudes and phases are not sufficient to constrain theoretical models of Epsilon Cephei. We find no evidence for rotational splitting or the large separation among the frequencies detected in the WIRE data set. To be able to identify oscillation frequencies in delta scuti stars with the method we have applied, it is crucial to obtain more complete coverage from multi-site campaigns with a long time baseline and in multiple filters. This is important when planning photometric and spectroscopic ground-based support for future satellite missions like COROT and KEPLER.Comment: 13 pages, 12 figures, 4 tables. Fig. 4 reduced in quality. Accepted by A&

Ultra-deep 31.0-50.3 GHz spectral survey of IRC+10216

51 pags., 43 figs., 3 tabs.Context. The carbon-rich envelope of the asymptotic giant branch star CW Leo, IRC+10216, is one of the richest molecular sources in the sky. Available spectral surveys below 51 GHz are more than 25 years old, and new work is needed. Aims. Characterizing the rich molecular content of this source, specially for heavy species, requires carrying out very sensitive spectral surveys at low frequencies. In particular, we have achieved an rms in the range 0.2-0.6mK per MHz. Methods. Long Q band (31.0-50.3 GHz) single-dish integrations were carried out with the Yebes-40m telescope using specifically built receivers. The most recent line catalogs were used to identify the lines. Results. The data contain 652 spectral features, corresponding to 713 transitions from 81 species (we count the isomers, isotopologs, and ortho/para species separately). Only 57 unidentified lines remain with signal-to-noise ratios ≤3. Some new species and/or vibrational modes have been discovered for the first time with this survey. Conclusions. This IRC+10216 spectral survey is by far the most sensitive survey carried out to date in the Q band. It therefore provides the most complete view of IRC+10216 from 31.0 to 50.3 GHz, giving unique information about its molecular content, especially for heavy species. Rotational diagrams built from the data provide valuable information about the physical conditions and chemical content of this circumstellar envelope.We thank Ministerio de Ciencia e Innovación of Spain for funding support through projects PID2019-106110GB-I00, PID2019- 107115GB-C21/AEI/10.13039/501100011033, PID2019-106235GB-I00, and grant FJCI-2016-27983 for CB. We also thank ERC for funding through grant ERC-2013-Syg-610256-NANOCOSMOS. M.A. thanks MICIU for grant RyC2014-16277

EP05.02-003 Durvalumab after Chemoradiotherapy (CRT) in Unresectable Stage III NSCLC. Comparative Study of Two Cohorts in the Real-World Setting

[EN] Introduction: Durvalumab is the new standard of care for unresectable locally advanced NSCLC, with PD-L1 _1% and who did not have progression after CRT treatment in the European Union. Our study compares the effectiveness and the frequency of radiation pneumonitis in patients treated with concurrent CRT with or without durvalumab consolidation during the same period in real clinical practice. Methods: A single-center retrospective study. 71 treated patients with unresectable stage III NSCLC were included between March 2018 and December 2021, 37 with CRT followed by durvalumab and 34 with CRT alone. Real-world progression-free survival (rwPFS) and real-world overall survival (rwOS) were calculated since the date of the end CRT. Propensity score matching (PSM) 1:1 was used to account for differences in baseline characteristics. Results: Median age was 67 years (range 46-82). 25.4% of the patients were _75 years old. 78.9% were men and 53.5% former smokers. 54.9% had squamous histology and 28%, 51% and 21% stage IIIA, IIIB and IIIC disease, respectively. The most used scheme was carboplatinpaclitaxel (43.7%), receiving induction chemotherapy in up to 54.9% of patients. 73.2% received between 60-66 Gy doses of radiotherapy. Median time from end of CRT to onset durvalumab was 44 days (range 13-120) with a median of 14 infusions (range 6-27). Of the 34 patients without durvalumab treatment, the expression PD-L1 <1% (58.8%) was the most frequent cause for rejecting consolidation therapy. After PSM analysis, patients distributions were well balanced. With a median follow-up of 19.7 months (range 1.4-36.6); median rw-PFS was 9.3 months (95% CI, 5-13.5) without durvalumab and 17 months (95% CI, 11-22.9) with durvalumab (p¼0.013). Median rw-OS was 19.3 months (95% CI, 3.8-34.8) without durvalumab and 29.9 months (95% CI, 23.3-36.6) with durvalumab (p¼0.241) with a rw-OS% at 6, 18 and 24 months of 90%, 62% and 49% vs 100%, 86% and 74%, respectively. The rate of radiation pneumonitis was more frequent with durvalumab consolidation (56.8% against 44.1%), (p¼0.346), especially within 3 months after CRT. G3 pneumonitis was only observed in the consolidation therapy. Conclusions: Our results demonstrate the effectiveness of durvalumab consolidation after CRT in real-world patients with unresectable stage III NSCLC. Further sample and longer follow-up are required to obtain more accurate results. Active surveillance and appropriate management for radiation pneumonitis are needed, in especially in candidates for consolidation treatmentS

Mechanical and electromagnetic design of the vacuum vessel of the SMART tokamak

The SMall Aspect Ratio Tokamak (SMART) is a new spherical device that is currently being designed at the University of Seville. SMART is a compact machine with a plasma major radius (R) greater than 0.4 m, plasma minor radius (a) greater than 0.2 m, an aspect ratio (A) over than 1.7 and an elongation (k) of more than 2. It will be equipped with 4 poloidal field coils, 4 divertor field coils, 12 toroidal field coils and a central solenoid. The heating system comprises of a Neutral Beam Injector (NBI) of 600 kW and an Electron Cyclotron Resonance Heating (ECRH) of 6 kW for pre-ionization. SMART has been designed for a plasma current (I) of 500 kA, a toroidal magnetic field (B) of 1 T and a pulse length of 500 ms preserving the compactness of the machine. The free boundary equilibrium solver code FIESTA [1] coupled to the linear time independent, rigid plasma model RZIP [2] has been used to calculate the target equilibria taking into account the physics goals, the required plasma parameters, vacuum vessel structures and power supply requirements. We present here the final design of the SMART vacuum vessel together with the Finite Element Model (FEM) analysis carried out to ensure that the tokamak vessel provides high quality vacuum and plasma performance withstanding the electromagnetic j×B loads caused by the interaction between the eddy currents induced in the vessel itself and the surrounding magnetic fields. A parametric model has been set up for the topological optimization of the vessel where the thickness of the wall has been locally adapted to the expected forces. An overview of the new machine is presented here.This work received funding from the Fondo Europeo de Desarollo Regional (FEDER) by the European Commission under grant agreement numbers IE17-5670 and US-15570. This work has been carried out within the framework of the EUROfusion Consortium and has received funding from the Euratom research and training programme 2014-2018 and 2019-2020 under grant agreement No 633053. The views and opinions expressed herein do not necessarily reflect those of the European Commission

Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer : results from the Spanish early access program

Altres ajuts: Roche Farma, S.A.This retrospective observational study analyzed the clinical characteristics, treatment patterns and outcomes of 120 patients with advanced ALK-positive nonsmall-cell lung cancer (ALK+ NSCLC) according to data collected between November 2019 and October 2020 in 38 Spanish hospitals. Patients had progressed after 1-5 prior treatment lines (which included crizotinib in any prior line) and received subsequent therapy with alectinib in a local expanded access program. Median age was 58.7 years, 50% of patients were female, 64.1% had ECOG PS of 0-1, 85% presented stage IV, 95% had adenocarcinoma histology and 20.8% had brain metastases. After a median 9.6 months of alectinib treatment, objective response rate (ORR) was 54.5%, disease control rate (DCR) was 80%, median progression-free survival (PFS) was 9.4 months and median overall survival (OS) was 24.1 months. Patients with brain metastases achieved an intracranial DCR of 71.4%. Adverse events (AEs) were reported in 35.8% of patients (14.2% of AEs were grade ≥3). Over 40% of patients received some treatment after alectinib, most frequently lorlatinib (65.2%) and brigatinib (32.6%). This study provides information on real-world treatment patterns and confirms the tolerability and prolonged PFS and OS observed with alectinib in clinical trials, in unselected pretreated patients with advanced ALK+ NSCLC

EP05.02-002 Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)?

[EN] Introduction: Durvalumab received EMA approval as consolidation therapy (CT) for unresectable stage III NSCLC with PD-L1 _1% and who did not have progression after CRT. Our objective was to analyze in real clinical practice the effectiveness of durvalumab and explore the clinical factors that may be associated with the benefit from CT. Methods: Retrospective study was made at Hospital of Leon (Spain), including 37 patients with locally advanced NSCLC treated with durvalumab after CRT treatment between March 2018 and october 2021 (40.5% patients were included in the durvalumab early access program). The neutrophil-to-lymphocyte ratio (NLR) could identified after CRT as a factor that may be benefit from durvalumab. Results: Median age was 67 years (range 46-82 years). 40.5% of patients were _70 years old. 78.4% were male and 51.4% smokers. 54% had non-squamous histology. PD-L1 expression was <1% in 5% and not available in 8% patients. 2.7% ROS1 rearrangements, 5.4% KRAS mutations and not available in 43.2% patients. Stage IIIA, IIIB, IIIC disease were 24.3%, 54.1% and 21.6%, respectively. Median time from end of CRT to onset durvalumab was 44 days (range 13-120 days). Overall median CT duration was 214.8 days (range 69-399 days) with a median of 14 infusions (range 6-27 infusions). With a median follow up of 19.7 months (range 1.4-34.9 months); 67.6% had stopped CT: 37.8% due to completing treatment, 16.2% disease progression, 10.8% adverse event and 2.7% due to COVID19 infection. Median real-world progressionfree survival (rwPFS) was 17 months (95% CI, 11-23). Median realworld overall survival (rwOS) was 29.9 months (95% CI, 23.3-36.6). % rwOS at 6, 18 and 24 months were 100%, 86.9% and 74.5%, respectively. For patients with post-CRT NLR not exceeding the cohort median value of 6, receipt of durvalumab was associated with an improvement in rwOS (median not reached vs 25.7 months; p¼0.025). 56.8% patients had any grade of radiation pneumonitis (median time from CRT start: 119 days [range 36-241 days]). Of these, 19% patients developed worsening of radiation pneumonitis with durvalumab. 54,1% developed immune-mediated toxicity, mostly G1-2 (85.1%). Conclusions: Our results demonstrate the effectiveness of durvalumab consolidation in this patients population in a real-life setting. We identified low NLR after CRT as a potentially predictive factor for the benefit of CT in locally advanced NSCLC.S

Comparison of fiber effect on glycemic index and glycemic load in differents types of bread

Indexación: Scopus; Redalyc.Existen diversos alimentos que contienen como nutriente principal hidratos de carbono, destacando entre ellos el pan por su masivo consumo a nivel mundial. Numerosos estudios se han llevado a cabo con el fin de reducir su índice glicémico, sin embargo, aún existe controversia sobre la acción de la fibra dietética en la disminución del IG en este alimento. Este estudio determinó el efecto de la fibra dietética sobre el índice glicémico y carga glicémica en dos tipos de panes comerciales en 23 individuos sanos quienes consumieron aleatoriamente 3 diferentes productos, de 50 g de carbohidratos cada uno, durante 6 días: pan blanco (PH), pan integral (PF), y solución glucosada como producto de referencia (SG). Se midió glicemia en ayunas y post-prandial a los tiempos 15, 30, 45, 60, 90 y 120 min. La insulina fue medida en el minuto 0 y 120 min. El área bajo la curva de glicemia resultó más baja para ambos tipos de pan PH 13589 ±1557, PF 12005 ±1254 que para el producto de referencia SG 14089 ±1245. Los valores del índice glicémico PH 68,55 ±1,2 y PF 62,10 ±1,3 y carga glicémica PH 16,45 ±1,4 resultaron más bajos para el pan con mayor aporte de fibra 9,93 ± 1,1, sin diferencias en la concentración de insulina, sugiriendo que la cantidad de carbohidratos y tipo de fibra contenidos en el pan integral, pueden considerarse factores intrínsecos en su composición nutricional, capaces de afectar la respuesta glicémica post- ingesta de estos productos en individuos sanos.There are several foods that contain carbohydrates as the main nutrient, being one of the most important the bread for its massive worldwide consumption. Numerous studies have been done in order to reduce its glycemic index, however there is still controversy about the action of dietary fiber in the decrease of GI in this product. In this study, it was determined the effect of dietetic fiber on glycemic index and glycemic load in two types of commercial breads in 23 healthy individuals who randomly consumed 3 different products during 6 days of 50g of carbohydrates each: white bread (PH), whole wheat bread (PE) and glucose solution as reference product (SG). Fasting and postprandial glycemia was measured at times 15, 30, 45, 60, 90 and 120 minutes. Insuline was measured at 0 min and 120 min. The area under de glycemia curve was lower for both bread types PH 13589 ±1557, PF 12005 ±1254 than for the reference product SG 14089 ±1245. The values of the glycemic index PH 68,55 ±1,2 and PF 62,01 ±1,3 and glycemic load PH 16.45 ±1,4 were lower for bread with more amount fiber 9,93 ± 1,1, with no difference in insulin concentration, suggesting that the amount of carbohydrates and fiber type contained in whole wheat bread can be considered intrinsic factors in bread composition, affecting the post-intake glycemic response of this type of products in healthy individuals.http://www.redalyc.org/articulo.oa?id=5594990800